We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

50 hedge funds and large institutions have $51.5M invested in Astria Therapeutics in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,421% more call options, than puts

Call options by funds: $7.71M | Put options by funds: $306K

575% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 4

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

107% more capital invested

Capital invested by funds: $24.9M → $51.5M (+$26.6M)

85% more funds holding

Funds holding: 27 → 50 (+23)

1.85% more ownership

Funds ownership: 5.6% → 7.45% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
50
Holders Change
+23
Holders Change %
+85.19%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
11
Reduced
5
Closed
4
Calls
$7.71M
Puts
$306K
Net Calls
+$7.41M
Net Calls Change
+$2.74M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.17M
2
State Street
State Street
Massachusetts
+$1.2M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$735K
4
N
Nuveen
North Carolina
+$643K
5
Northern Trust
Northern Trust
Illinois
+$458K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$184K
2
WVP
Worth Venture Partners
New Jersey
-$148K
3
JP Morgan Chase
JP Morgan Chase
New York
-$38K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$35.9K
5
Victory Capital Management
Victory Capital Management
Texas
-$24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$19.6M – – –
BlackRock
2
BlackRock
New York
$7.13M +$5.17M +145,147 +367%
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.79M +$409K +11,474 +10%
SB
4
Samsara BioCapital
California
$1.93M – – –
SHI
5
SV Health Investors
Massachusetts
$1.84M – – –
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$1.64M +$54.6K +1,532 +4%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.48M +$735K +20,636 +117%
State Street
8
State Street
Massachusetts
$1.3M +$1.2M +33,592 New
Blackstone Inc
9
Blackstone Inc
New York
$1.29M – – –
PHP
10
Parkman Healthcare Partners
Connecticut
$1M – – –
Northern Trust
11
Northern Trust
Illinois
$994K +$458K +12,868 +100%
WVP
12
Worth Venture Partners
New Jersey
$883K -$148K -4,165 -15%
N
13
Nuveen
North Carolina
$697K +$643K +18,061 New
OC
14
Oppenheimer & Co
New York
$691K -$4.27K -120 -0.7%
Renaissance Technologies
15
Renaissance Technologies
New York
$669K +$283K +7,953 +85%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$620K +$31.5K +885 +6%
BCM
17
Bridgeway Capital Management
Texas
$581K +$210K +5,883 +64%
CRC
18
Curi RMB Capital
Illinois
$452K -$11K -309 -3%
Two Sigma Investments
19
Two Sigma Investments
New York
$417K +$385K +10,796 New
WG
20
Winton Group
United Kingdom
$386K +$66.5K +1,868 +23%
Charles Schwab
21
Charles Schwab
California
$340K +$314K +8,808 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$276K +$256K +7,180 New
Goldman Sachs
23
Goldman Sachs
New York
$270K +$250K +7,007 New
UBS Group
24
UBS Group
Switzerland
$246K +$227K +6,378 New
Wells Fargo
25
Wells Fargo
California
$219K +$201K +5,645 +33,206%
1
2 3

ATXS Hedge Fund Activity: Q2 2020 in Review

50 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2020, worth a combined $51.5M — up 107% from $24.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ATXS positions and 4 closed out — a net gain of 23 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $5.17M. The largest seller was OrbiMed, exiting entirely with an estimated $184K sold.

  • 50 institutional investors held Astria Therapeutics (ATXS) as of Q2 2020, up from 27 in Q1 2020.
  • Funds reported $51.5M of Astria Therapeutics stock for Q2 2020, up 107% quarter-over-quarter.
  • 27 funds opened new Astria Therapeutics positions in Q2 2020 and 4 closed out, a net change of +23 holders.
  • The largest Astria Therapeutics buyer in Q2 2020 was BlackRock, an estimated $5.17M added.
  • The largest Astria Therapeutics seller in Q2 2020 was OrbiMed, an estimated $184K sold.

Based on aggregated 13F filings for Q2 2020.